Page 8 - Robert Barrow News Today

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have covered the stock in the last […]

Mind Medicine Inc , , , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement...

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, August 3rd. Analysts expect the company to announce earnings of ($0.54) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Mind […]

North Star Investment Management Corp. grew its stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 27,551.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,125 shares of the company’s stock after buying an additional 9,092 shares during […]

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) has been assigned an average recommendation of “Buy” from the eight brokerages that are covering the company, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year […]

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) CEO Robert Barrow sold 15,502 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $3.20, for a total value of $49,606.40. Following the sale, the chief executive officer now directly owns 623,457 […]

MindMed’s (NASDAQ: MNMD) heated proxy battle over R&D strategy might finally be coming to an end.

Longacre Square Partners guided Mind Medicine as the psychedelic drug company declared victory in its proxy contest.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees – CEO ...

Believes Socially Responsible Investment Principles Support FCM’s Plan to Bring MM-120 To the Market in 2026 to Benefit Millions with Mental Health...